Extensive-disease small-cell lung cancer: The thrill of victory; The agony of defeat

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 658-665

  Aisner, Joseph ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030031710     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.658     Document Type: Review

References (70)

1. Cohen MH, Matthews MJ: Small cell bronchogenic carcinoma: A distinct clinicopathological entity. Semin Oncol 1:234-243, 1978
2. Aisner J, Alberto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67:37-43, 1983
3. Aisner J: Treatment of limited-disease small cell lung cancer. Semin Oncol 19:51-58, 1992 (suppl 13)
4. Stephens RJ, Girling DJ, Machin D, et al: Medical Research Council Lung Cancer Working Party: Treatment related deaths in small cell lung cancer trials: Can patients at risk be identified? Lung Cancer 11:259-274, 1994
5. Comis RL: Developments in therapy for extensive-disease small cell lung cancer. Semin Oncol 19:45-50, 1992 (suppl 13)
6. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-240, 1990
7. Evans WK, Feld R, Murray N, et al: Superiority of an alternating non cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451-458, 1987
8. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
9. Kaasa S: Psychosocial aspects of patients with lung cancer in controlled clinical trials. Cancer Treat Res 45:325-355, 1989
10. Eguchi K, Etou H, Miyachi S, et al: A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer 30A:188-194, 1994
11. Gridelli C, Ianniello GP, Maiorino A, et al: Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. Am J Clin Oncol 17:160-162, 1994
12. Fukuoka M, Masuda N, Takad M, et al: Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol 21:43-46, 1994, (suppl 7)
13. Ohnoshi T, Hiraki S, Ueoka H, et al: Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etopside hybrid chemotherapy in small cell lung cancer. Cancer 72:1597-1601, 1993
14. Goss GD, Vincent M, Germond C, et al: Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer. Am J Clin Oncol 16:295-300, 1993
15. Livingston RB, Crowley JJ, Thompson T, et al: Prolonged, alternating chemotherapy for extensive small cell lung cancer: A Southwest Oncology Group study. Cancer 71:3509-3513, 1993
16. Nou E, Lamberg K, Brodin O: Etoposide versus methotrexate in small cell bronchial carcinoma. A randomized study of two types of four-drug chemotherapy regimens. Acta Oncol 31:853-860, 1992
17. Aisner J, Whitacre MY, Budman DR, et al: Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother Pharmacol 29:435-438, 1992
18. Clamon G, Herndon J, Perry MC, et al: Interleukin-2 activity in patients with extensive small-cell lung cancer: A phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 85:316-320, 1993
19. Estape J, Grau JJ, Daniels M, et al: Intensive treatment of small-cell carcinoma of the lung with cisplatin (CDDP), etoposide (VP16), cyclophosphamide (CY), and doxorubicin (DRB). Proc Am Soc Clin Oncol 9:A969, 1990 (abstr)
20. Evans WK, Stewart D, Logan D, et al: A phase II study of ifosfamide in combination with etopside and cisplatin in the treatment of extensive small cell lung cancer. Semin Oncol 19:51-56, 1992 (suppl 12)
21. Calvo FA, Hidalgo OF, Gonzales F, et al: Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 70:2624-2630, 1992
22. Gatzemeier U, Hossfeld DK, Neuhauss R, et al: Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol 10:818-823, 1992
23. Bando H, Takishita Y, Ogura T, et al: Alternating chemotherapy with cyclophosphamide/Adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group. Jpn J Clin Oncol 21:435-439, 1991
24. Bianco AR, Stefani S, Gridelli C, et al: Intensive alternating chemotherapy and high dose chest radiotherapy in small cell lung cancer. Tumori 77:437-441, 1991
25. Loehrer PJ Sr, Rynard S, Ansari R, et al: Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer 69:669-673, 1992
26. Eich F, Sybrecht GH: Bicyclic alternating polychemotherapy of limited and extensive stage small-cell lung cancer (SCLC). Proceedings of the 1990 World Congress on Lung Health, Boston, MA, 1990 (abstr A266).
27. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991
28. Wolf M, Pritsch M, Drings P, et al: Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: A german multicenter randomized trial of 321 patients. J Clin Oncol 9:614-624, 1991
29. Taylor CW, Crowley J, Williamson SK, et al: Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals. A Southwest Oncology Group pilot study. J Clin Oncol 8:1811-1817, 1990
30. Gennatas C, Dardoufas C, Kouvaris J, et al: A Pilot study of an alternating chemotherapy (CT) regime in extensive disease (ED) small cell carcinoma of the lung (SCLC). Proc Am Soc Clin Oncol 9:A980, 1990 (abstr)
31. Eberhardt W, Ochel HJ, Grabke I, et al: Carboplatin, etoposide, and vincristine (CEV) plus/minus GM-CSF in the treatment of small cell lung cancer (SCLC): A phase II study. Proc Am Soc Clin Oncol 9:A947, 1990 (abstr)
32. Smith IE, Perren TJ, Ashley SA, et al: Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small cell cancer. J Clin Oncol 8:899-905, 1990
33. Thatcher N, Lorrigan P, Stout R: Intensive combined-modality therapy in small cell lung cancer. Semin Oncol 21:9-22, 1994 (suppl 6)
34. Bishop JF, Kefford R, Raghavan D, et al: Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. Cancer Chemother Pharmacol 25:367-370, 1990
35. Miles DW, Earl HM, Souhami RL, et al: Intensive weekly chemotherapy for good prognosis patients with small cell lung cancer. J Clin Oncol 9:280-285, 1991
36. Souhami RL, Rudd R, Ruiz de Elvira MC, et al: Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. J Clin Oncol 12:1806-1813, 1994
37. Alba E, Breton JJ, Alonso L, et al: Alternating chemotherapy for small cell lung cancer. A twelve week schedule of six drugs. Ann Oncol 3:31-35, 1992
38. Jones AM, Holborn J, Ashley S, et al: CVM versus ACE in the treatment of small cell lung cancer. Oncology 50:10-15, 1993 (suppl 2)
39. Miles DW, Souhami RL, Harper PG, et al: A randomized trial comparing 3-weekly vs weekly chemotherapy in patients with small-cell lung cancer. Br J Cancer 65:11, 1992 (suppl 16; abstr)
40. Miller AA, Herndon JE, Hollis DR, et al: Schedule dependency of 21 day oral versus three day intervenous etoposide in combination with intravenous cisplatin in extensive stage small cell lung cancer: A randomized phase III study of the cancer and leukemia group B. J Clin Oncol 8:1871-1879, 1990
41. Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. European Organization for Research and Treatment of Cancer. Lung Cancer Cooperative Group. J Clin Oncol 11:1230-1240, 1993
42. Maksymiuk AW, Jett JR, Earle JD, et al: Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12:70-76, 1994
43. Wampler GL, Heim WJ, Ellison NM, et al: Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small cell lung carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 9:1438-1445, 1991
44. Bleehan NM, Girling DJ, Machin D, et al: A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate, and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC): Survival and prognostic factors Medical Research Council Lung Cancer Working Party. Br J Cancer 68:1150-1156, 1993
45. Shepard FA, Amdemichael E, Evans WK, et al: Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 42:64-70, 1994
46. Bleehan NM, Girling DJ, Machin D, et al: A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate, and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Working Party. Br J Cancer 68:1150-1156, 1993
47. Saka H, Watanabe A, Shimokata K, et al: Chronic oral etoposide and carboplatin in small cell lung cancer (SCLC) as a first-line chemotherapy: A poor survival? Proc Am Soc Clin Oncol 12:A1157, 1993 (abstr)
48. Clark PI, Cottier B: The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19:36-39, 1992 (suppl 4)
49. Carney DN, Grogan L, Smit EF, et al: Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 17:49-53, 1990 (suppl 2)
50. Hartlapp JH, Klieche L, Kesseler H, et al: Etoposide (VP16) and vincristine as treatment in extensive stage small cell lung cancer (SCLC). J Chemother Infect Dis Malign A476, 1989 (suppl, abstr)
51. Kamthan AG, Lind MJ, Thatcher N, et al: Ifosfamide, doxorubicin, and etoposide in small cell lung cancer patients with poor prognosis. Eur J Cancer 26:691-694, 1990
52. Ardizzoni A, Pennucci C, Fusco V, et al: Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide. Anticancer Res 9:937-939, 1989
53. Michel G, Leyvraz S, Bauer J, et al: Weekly carboplatin and VM26 for elderly patients with small cell lung cancer. Ann Oncol 5:369-370, 1994
54. Slevin ML: Low-dose oral etoposide: A new role for an old drug. J Clin Oncol 8:1607-1609, 1990
55. Osterlind K, Ihde DC, Ettinger DS, et al: Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 67:3-8, 1983
56. Osterlind K, Anderson PK: Prognostic factos in small cell lung cancer: Multivariate model based on 728 patients with chemotherapy with or without irradiation. Cancer Res 46:4189-4194, 1986
57. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small cell lung cancer: An analysis of the 2,560-patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990
58. Sagman U, Maki E, Evans WK, et al: Small cell carcinoma of the lung: Derivation of a prognostic staging system. J Clin Oncol 9:1639-1649, 1991
59. Aisner J, Whitacre MY, Abrams J, et al: Adriamycin, Cytoxan, etoposide (ACE) and platinum, Adriamycin, Cytoxan, etoposide (PACE) for small cell carcinoma of the lung. Semin Oncol 73:1189-1193, 1986
60. Wiesenfeld M, Jett JR, Su JQ, et al: Phase II trial of edatrexate in small cell lung cancer. Cancer 73:1189-1193, 1994
61. Dalley D, Dalley D, Brigham B: Phase I/II study of oral etoposide and modulation of drug resistance with ketoconazole (KCZ) in small cell lung cancer (SCLC). Proceedings of the Fourth International Congress on Anticancer Chemotherapy, Paris, France, 1993, p 85
62. Cormier Y, Eisenhauer E, Gregg R, et al: Gemcitabine: an active new agent in patients (pts) with previously untreated small cell lung cancer (SCLC). A phase II trial of the NCI Canada Clinical Trials Group (NCIC CTG); Proc Am Soc Clin Oncol 12:A1097, 1993 (abstr)
63. Ettinger DS, Finkelstein DM, Sarma R, et al: Phase II study of Taxol in patients (pts) with extensive-stage small cell lung cancer (SCLC): An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 12:A1094, 1993 (abstr)
64. Ettinger D, Finkelstein D, Ritch P, et al: Randomized trial of single agents vs. combination chemotherapy in extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 11:A988, 1992 (abstr)
65. Ettinger DS, Finkelstein DM, Abeloff MD, et al: Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 84:1077-1084, 1992
66. Giaccone G: Teniposide alone and in combination for small cell lung cancer. Semin Oncol 19:75-80, 1992 (suppl 6)
67. Kleisbauer JP, Taytard A, Vergeret J, et al: Pirarubicin (P) phase II study in metastatic small-cell lung cancer (SCLC) without prior chemotherapy. A cooperative study of the Groupe Francais de Pneumo-Cancerologie (GFPC). Proc Am Assoc Cancer Res 31:A1169, 1990 (abstr)
68. Grant SC, Kris MG: Phase II trials in small cell lung cancer: Shouldn't we be doing better? J Natl Cancer Inst 84:1058-1059, 1992
69. Batist G, Ihde DC, Zabell A, et al: Small cell carcinoma of the lung: Reinduction therapy after late relapse. Ann Intern Med 98:424-474, 1983
70. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II study. J Clin Oncol 8:1613-1617, 1990